Drug Delivery Company, LLC

Delmarva Hemp, LLC

Other

Jeffrey David Benner

Steven M Cohen

Christopher Forrest Lumpkin

Naresh Kumar Reddy Vutukuru

Srinivasan Shanmugam

David Benton McGiffin

Larry Maurice Douglas

Pushkar Shrinivas Kulkarni

Henry Thomas Oakley, Jr

Paul Edward Tomaszewski

A method of fabricating an extended release subcutaneous medicinal dosage implant system which includes an implant fabricated from a highly homogeneously mixed composition including a medicinal agent in combination with release controlling polymers which include poly (DL-lactide) and polycaprolactone. In one implementation for treating an opioid disease, the formulation composition includes naltrexone at 40 weight percent, poly (DL-lactide) in the approximate range between 36 and 46.4 weight percent, and polycaprolactone in the approximate range between 24 and 11.6 weight percent. In addition, in order to provide anti-biofouling quality and prevent foreign body adsorption/interaction with the material of the implant, polyethylene glycol is added in a preferred content of 2.0%. The manufacturing process includes hot melt extrusion and a mini jet based implant formation stage with the optimized process space were the temperature of the process ranges from 170° C.-180° C., mixing time through the HME process ranging from 8 minutes to 12 minutes, and injection time ranging from 8 seconds to 12 seconds. The resulting implants have a uniquely shaped free of defects bio absorbable solid body.

Method of fabricating an extended release subcutaneous medicinal dosage implant system

A system for preparing a medicinal substance containing full spectrum of therapeutically desirable substances in naturally occurring proportions found in hemp plants, carried out by grinding a whole hemp plant to produce fine particles material, and exposing the fine particles material to an elevated pressure (11 PSI-15 PSI) and a reaction temperature maintained in a range of 230 F-250 F which is below a boiling point of the phyto-cannabinoids, terpenes and flavonoids, thus providing enhanced conditions for solvent-free extraction of the therapeutically desirable substances and diffusing the extracted substances into the carrier oil at an enhanced rate. Thus producing an infused oil final product containing a full spectrum phyto-cannabinoids, terpenes and flavonoids in naturally occurring proportions.

System for producing solvent free full spectrum cannibis extract

A method for preparing a medicinal substance containing full spectrum of therapeutically desirable substances in naturally occurring proportions found in hemp plants, is carried out by grinding a whole hemp plant to produce fine particles material, and exposing the fine particles material to an elevated pressure (11 PSI-15 PSI) and a reaction temperature maintained in a range of 230 F-250 F which is below a boiling point of the phyto-cannabinoids, terpenes and flavonoids, thus providing enhanced conditions for solvent-free extraction of the therapeutically desirable substances and diffusing the extracted substances into the carrier oil at an enhanced rate. Thus produced infused oil final product contains full spectrum phyto-cannabinoids, terpenes and flavonoids in naturally occurring proportions.

Method for solvent-free extraction and concentration of full spectrum of cannabinoids in a carrier oil

An extended-release bio absorbable subcutaneous medicinal dosage delivery implant system includes an implant fabricated from a highly homogeneously mixed composition including a medicinal agent in combination with release controlling polymers which include poly (DL-lactide) and polycaprolactone. In one implementation for treating an opioid disease, the formulation composition includes naltrexone at 40 weight percent, poly (DL-lactide) in the range between 36 and 46.4 weight percent, and polycaprolactone in the range between 24 and 11.6 weight percent. In addition, in order to provide anti-biofouling quality and prevent foreign body adsorption/interaction with the material of the implant, polyethylene glycol is added in a preferred content of 2.0%. The manufacturing process includes hot melt extrusion and a mini jet based implant formation stage with the optimized process space were the temperature of the process ranges from 170&#xb0; C.-180&#xb0; C., mixing time through the HME process ranging from 8 minutes to 12 minutes, and injection time ranging from 8 seconds to 12 seconds. The resulting implants have a uniquely shaped free of defects bio absorbable solid body.

Extended release bioabsorbable subcutaneous medicinal dosage delivery implant system

A contact lens assembly for non-sliding, non-sutured, hands-free ophthalmic procedures utilizes a magnetically actuated anchoring mechanism operatively coupled between the contact lens assembly and a modified eye speculum applied to eyelids during ophthalmic procedure. The anchoring mechanism is configured with magnetically cooperating anchoring members, one coupled to the contact lens assembly, and another secured to a wire loop member of the modified eye speculum. After the eye speculum is applied to the eyelids to displace and stabilize the eyelids and secure the anchoring member in place, and the contact lens assembly is placed on the cornea of the eye and centered, he magnetically cooperating anchoring members are brought in contact, and thus secure the contact lens assembly at the surgical site.

Non-sliding and non-sutured contact lens system for ophthalmic procedures

A subcutaneous implant system is applicable in a variety of surgical procedures and includes a balloon shaped implant formed from a bioresorbable material and is capable of assuming deflated and inflated configurations. The balloon shaped implant is inserted, in its deflated configuration, into the patient's body, and subsequently is inflated by filling the balloon shaped implant with a medicinal agent. The balloon shaped implant filled with the medicinal agent remains in the body and permits a steady-state release of the medicinal agent therefrom. The balloon shaped implant has a wall which may be formed from either a solid material which is impermeable to the medicinal agent, or a porous material. The medicinal agent egresses from the interior of the balloon shaped member in a controlled manner provided by a mechanism which may include a permeable membrane, a check valve, a flap valve, openings in a porous wall of the balloon shaped member, and combinations thereof. Upon the medicinal agent has been depleted, the balloon shaped implant is 'naturally removed' from the body through bio-dissolution in the patient's body.

Sub-cutaneous medicinal dosage delivery implant system

A non-sliding, non-sutured hands-free contact lens assembly for ophthalmic procedures utilizes a number of microstructures strategically placed on the bottom of either the contact lens or the bottom of a contact lens holder ring. After the contact lens, or the contact lens assembled with the contact lens holder ring, is placed on the cornea of the eye and centered, a surgeon applies downward pressure either on the contact lens itself or on the lens holder ring. This secures the lens assembly to the cornea due to increased friction between the microstructures and the tissues of the eye when the microstructures penetrate through the tear film and, optionally, viscous solution film and into the contact with superficial layer of cornea or other parts of the eye, thus temporarily anchoring the contact lens, or lens holder, to the desired surgical site.

A bioresorbable drug eluting intravitreal implant system includes a syringe with a chamber containing a medicinal drug. A balloon is releasably secured to a needle where the needle has a central section chamber in fluid communication with a chamber in the syringe. The needle central section has an opening formed through a wall for transporting the medicinal drug to the interior of the balloon subsequent to insertion of the needle through the sclera of a patient's eye.

Bioresorbable drug eluting intravitreal implant system and method

A harvester is provided for harvesting a plant similar to or like sorghum having a stalk and a grain head. The harvester includes a combine vehicle, a lower row crop cutter mechanism, and an upper grain cutter mechanism. The lower row crop cutter mechanism is mounted to a connecting portion of the combine vehicle for cutting plant stalks at a lower end of the plant. The upper grain cutter mechanism is coupled to a lower section of the combine vehicle and is vertically displaced from the lower row crop cutter mechanism for cutting the grain head at upper end of the plant simultaneously with the cutting of the plant stalk by the lower row crop cutter mechanism.

Growing community of inventors

Salisbury, MD, United States of America

Jeffrey David Benner